Identify Treatment Response and Recurrence Early
Monitor Immunotherapy Response
Assess treatment effectiveness using serial monitoring in patients with skin cancers
identify response to immune checkpoint inhibitor treatment earlier1
Evaluate risk & detect recurrence earlier in patients with Merkel cell carcinoma
risk of recurrence within 60 days of a positive Signatera™ test2
Monitor Treatment Response in Skin Cancers
Understanding if immunotherapy is working can be a clinical challenge
The Signatera™ Residual Disease Test can help assess treatment effectiveness, clarify indeterminate imaging, and identify exceptional responders to help you make the most informed decisions for your patients with skin cancer.1,2
Explore the Skin Cancer Data
- Assess prognosis and detect recurrence earlier in patients with Merkel cell carcinoma using serial ctDNA testing.2
Provide Confidence for Patients With Skin Cancer
After Jeffrey started dual immunotherapy for his metastatic melanoma, Signatera™ showed a dramatic drop in his ctDNA levels and helped provide assurance that his treatment was working.
Watch Jeffrey’s story to learn how his oncology team used Signatera™ to help guide his care and restore his confidence in his future.
Read the Published Data
Read how Signatera™ combined with standard imaging can predict immunotherapy response as early as 6 weeks into treatment.1
Review data demonstrating that ctDNA status is associated with risk of relapse in patients with stage III melanoma.3
Merkel Cell Carcinoma
Learn how Signatera™ can be used as a predictive biomarker regardless of MCPyV status.2
Personalize the Skin Cancer Treatment Journey
Partner with Natera to get comprehensive and streamlined genomic testing results to support individualized care.
|Signatera™||Highly sensitive and personalized tumor-informed test for molecular residual disease (MRD) detection|
|Altera™||Comprehensive tissue-based genomic profiling for clinically relevant somatic mutations/biomarkers (eg BRAF, CDKN2A, NRAS, TMB) with no additional sample when ordered with Signatera|
|Empower™||Germline genetic test for commonly screened genes in melanoma (eg BRCA1/BRCA2, TP53, CDKN2A, CDK4, BAP1, PTEN, MITF)|
Learn More About Signatera in Skin Cancers
Signatera in Melanoma
Read about Signatera™’s clinical utility and data for MRD assessment, recurrence monitoring, and IO treatment response monitoring.
IO Monitoring Brochure
Learn how Signatera™ can be used to assess immunotherapy response as early as 6 weeks into treatment for patients with skin cancers and other solid tumors.1
After Steven was diagnosed with metastatic melanoma, his oncologist used Signatera™ to track his ctDNA levels. Watch Steven’s story to learn how Signatera helped him rediscover hope.
Learn how Signatera™ can help identify progression in the absence of clear imaging results.
Real World Clinical Applications
Learn about Signatera™ in clinical practice from Dr. Andrew S. Poklepovic in this on-demand webinar and Q&A.
Find information about billing, including Medicare coverage for pan-cancer immunotherapy monitoring, stage II/III CRC, and muscle invasive bladder cancer.
Is Signatera™ right for your patients with skin cancer?
1Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1:873-881. https://doi.org/10.1038/s43018-020-0096-5
2Akaike T, et al. Circulating tumor DNA correlates with Merkel cell carcinoma tumor burden and helps early detection of recurrence. ASCO, Chicago, Illinois, June 3-7, 2022.
3Eroglu Z et al. Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Oral presentation presented at Society for Melanoma Research, Virtual Meeting, Oct 28-31, 2021.